| Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT04402541) | Cleave Therapeutics, Inc. | 2020-06-08 |
| Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (NCT04906031) | First Affiliated Hospital of Jinan University | 2020-06-01 |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (NCT04256317) | Taiho Oncology, Inc. | 2020-05-21 |
| CPX-351 in Higher Risk Myelodysplastic Syndromes (NCT04273802) | Groupe Francophone des Myelodysplasies | 2020-04-29 |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide (NCT04361058) | SCRI Development Innovations, LLC | 2020-04-13 |
| SNS-301 Monotherapy in High Risk MDS and CMML (NCT04217720) | Sensei Biotherapeutics, Inc. | 2020-04-01 |
| CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML (NCT04151706) | Robert Lowsky | 2020-02-27 |
| Biologically Focused Therapy of Treatment-Refractory MDS Patients (NCT05245032) | Stanford University | 2020-02-18 |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS (NCT04055844) | Masonic Cancer Center, University of Minnesota | 2020-02-17 |
| A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS (NCT04044209) | Yale University | 2020-02-12 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (NCT03533816) | University of Kansas Medical Center | 2020-01-31 |
| AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration (NCT04263181) | Washington University School of Medicine | 2020-01-29 |
| Sterile Inflammation and Molecular Aberrations in MDS (NCT04313231) | Medical University Innsbruck | 2020-01-22 |
| Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia (NCT04296214) | Grupo Cooperativo de Hemopatías Malignas | 2020-01-01 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (NCT04036448) | Celgene | 2019-11-28 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT04013685) | Orca Biosystems, Inc. | 2019-11-21 |
| Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia (NCT04232241) | Universitätsklinikum Hamburg-Eppendorf | 2019-11-14 |
| Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation (NCT03836690) | University College, London | 2019-10-21 |
| Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS (NCT03920657) | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 2019-10-04 |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) (NCT04093570) | Taiho Oncology, Inc. | 2019-09-30 |
| An European Platform for Translational Research in Myelodysplastic Syndromes (NCT04174547) | Istituto Clinico Humanitas | 2019-09-30 |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) (NCT03057990) | Montefiore Medical Center | 2019-09-11 |
| Combining Active and Passive DNA Hypomethylation (NCT03999723) | Kirsten Grønbæk | 2019-09-11 |
| Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT03755414) | Washington University School of Medicine | 2019-09-04 |
| Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results (NCT04060485) | National Taiwan University Hospital | 2019-08-19 |
| Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL (NCT04053933) | University Hospital, Antwerp | 2019-08-01 |
| ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant (NCT03932643) | University of Nebraska | 2019-07-30 |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems (NCT03814005) | Takeda | 2019-07-10 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) (NCT03904134) | Center for International Blood and Marrow Transplant Research | 2019-06-14 |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (NCT03946670) | Novartis Pharmaceuticals | 2019-06-04 |
| Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia (NCT05931718) | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2019-06-01 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion (NCT03900715) | Celgene | 2019-05-20 |
| PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS (NCT03927261) | Precigen, Inc | 2019-05-20 |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome (NCT03503409) | Groupe Francophone des Myelodysplasies | 2019-05-14 |
| AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis (NCT03718143) | NYU Langone Health | 2019-05-08 |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes (NCT03446638) | University of Florida | 2019-05-01 |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation (NCT03843528) | Johns Hopkins All Children's Hospital | 2019-05-01 |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT03802695) | Orca Biosystems, Inc. | 2019-04-08 |
| IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome (NCT03744390) | Groupe Francophone des Myelodysplasies | 2019-04-02 |
| A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) (NCT03886662) | Lixte Biotechnology Holdings, Inc. | 2019-04-01 |
| A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT03915379) | Janssen Research & Development, LLC | 2019-03-28 |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS (NCT03884829) | Cyclacel Pharmaceuticals, Inc. | 2019-03-25 |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT (NCT03810196) | Children's Hospital of Philadelphia | 2019-03-01 |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies (NCT03885947) | Alla Keyzner | 2019-02-21 |
| A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes (NCT03746041) | University of Rochester | 2019-02-14 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (NCT03852407) | University of Liege | 2019-02-04 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial (NCT03735446) | Dana-Farber Cancer Institute | 2019-01-18 |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (NCT03682536) | Celgene | 2019-01-02 |
| Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples (NCT04251078) | Josep Carreras Leukaemia Research Institute | 2019-01-01 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (NCT03699475) | Bellicum Pharmaceuticals | 2018-12-27 |
| CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome (NCT03572764) | Washington University School of Medicine | 2018-12-14 |
| A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts (NCT04331483) | Centre Leon Berard | 2018-12-08 |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (NCT03612739) | Celyad Oncology SA | 2018-12-01 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (NCT03555955) | Jazz Pharmaceuticals | 2018-11-20 |
| Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (NCT03579875) | Masonic Cancer Center, University of Minnesota | 2018-11-13 |
| Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS (NCT03300492) | University Hospital, Basel, Switzerland | 2018-11-12 |
| Effect of Food on Blood Levels of ASTX727 (NCT03813186) | Astex Pharmaceuticals, Inc. | 2018-11-08 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS (NCT03059615) | Immune System Key Ltd | 2018-10-25 |
| Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS (NCT03660228) | Dana-Farber Cancer Institute | 2018-10-17 |
| Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant (NCT03588936) | Medical College of Wisconsin | 2018-09-14 |
| DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US (NCT02863458) | The Cleveland Clinic | 2018-09-01 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT (NCT03696537) | Naoyuki G. Saito, M.D., Ph.D. | 2018-08-29 |
| HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation (NCT03655145) | Assistance Publique - Hôpitaux de Paris | 2018-08-01 |
| Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS (NCT03502668) | Taiho Oncology, Inc. | 2018-07-27 |
| Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes (NCT03558386) | Center for International Blood and Marrow Transplant Research | 2018-07-23 |
| A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies (NCT03560882) | Joaquina Baranda | 2018-07-19 |
| Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients (NCT03594149) | Centre Henri Becquerel | 2018-07-18 |
| A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (NCT03573310) | Janssen Research & Development, LLC | 2018-07-13 |
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (NCT03434704) | Ciceri Fabio | 2018-06-18 |
| Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes (NCT03621241) | Centre Hospitalier Universitaire, Amiens | 2018-06-15 |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS (NCT03187288) | University Health Network, Toronto | 2018-05-25 |
| CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS (NCT03291444) | Zhujiang Hospital | 2018-05-05 |
| A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations (NCT03433781) | NYU Langone Health | 2018-05-01 |
| Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) (NCT03469661) | Fundacion CRIS de Investigación para Vencer el Cáncer | 2018-04-25 |
| Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation (NCT03483324) | Angiocrine Bioscience | 2018-04-24 |
| Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients (NCT03318159) | Seoul National University Hospital | 2018-04-20 |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) (NCT03377725) | Li Junmin | 2018-03-20 |
| TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid (NCT03397173) | Case Comprehensive Cancer Center | 2018-03-16 |
| HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies (NCT03232268) | Institut Paoli-Calmettes | 2018-03-09 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT03795779) | iCell Gene Therapeutics | 2018-03-01 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT04156256) | iCell Gene Therapeutics | 2018-03-01 |
| Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes (NCT03363399) | University Hospital, Grenoble | 2018-02-22 |
| IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome (NCT03175978) | IGF Oncology, LLC | 2018-02-21 |
| Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (NCT03306264) | Astex Pharmaceuticals, Inc. | 2018-02-15 |
| RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT (NCT03412266) | Peking University People's Hospital | 2018-02-01 |
| RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT (NCT03412409) | Peking University People's Hospital | 2018-02-01 |
| Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS (NCT03074006) | MedPacto, Inc. | 2018-01-04 |
| Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) (NCT03258359) | PersImmune, Inc | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab (NCT03286114) | University of Michigan Rogel Cancer Center | 2017-12-21 |
| Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (NCT03233074) | Centre Hospitalier Universitaire de Saint Etienne | 2017-11-17 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT (NCT03176849) | Phoenix Children's Hospital | 2017-11-01 |
| A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy (NCT03310918) | Massachusetts General Hospital | 2017-10-31 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML (NCT03138395) | University of Florida | 2017-09-15 |